Pfizer intends to pay $47.50 per share up front to acquire all of Metsera's stock, plus potentially $22.50 per share more in milestone payments as Metsera's drug candidates progress through trials to ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback